Welcome to Markets Desk, your midday read on what's moving money and markets.
Nvidia is dominating the conversation on two fronts today. The chip giant finds itself at the center of a governance controversy that critics say exposes a deeper flaw in how the S&P five hundred concentrates risk around a single name. With so much retirement capital indexed to Nvidia's weight, any scandal carries systemic implications well beyond one stock.
And yet the broader market is holding up. The S&P five hundred has largely shrugged off Nvidia's selloff, which tells you something important — investors are rotating attention back to the rest of the board, rediscovering that there are four hundred and ninety nine other companies in the index, and some of them are quietly doing the work.
Meanwhile, Eli Lilly is extending its remarkable run. New data showing tirzepatide's effectiveness in reducing sleep apnea severity sent the stock higher, adding another clinical use case to a drug already reshaping the obesity treatment landscape. For Lilly, each new indication is essentially a new revenue line, and Wall Street is pricing that in accordingly.
That's the tape. Markets Desk, signing off the floor.
